March 23, 2021 5:55pm

Back to my mantra, “How many times when we see highs, we say BYE not buy”

Pre-open indication results: 7 HITs and 1 MISS

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!

The Dow closed DOWN -308.05 points (-0.94 %); the S&P closed DOWN -30.07 points (-0.76%) while the Nasdaq also closed DOWN – 149.84 points (-1.12%)



Indexes fell on Tuesday after an afternoon slide led by shares of companies with the most to lose if there were any risks in the sustainability model.

Selling appears to largely be a “mean reversion” in a market left vulnerable by the substantial outperformance of cyclically sensitive stocks over technology shares and other growth stocks that had been the highest fliers during the stay-at-home phase of the pandemic. <MarketWatch>

The move was “less of a catalyst-driven” reaction “than necessarily an unwind of a trade that had gotten extended,” said Arthur Hogan, chief market strategist for National, my old friend.

Hopefully, vaccinations will improve optimism and reduce the elements and daily perceptions (it seems expressed in every move in life lately) of risk.

I was always a bullet or a beer type, but as I aged through this pandemic even, I get paranoid!


RegMed Investors’ (RMi) pre-open: “the beat-down goes on after one crash, another Q4 loss with merger ups risk paradigm. Reiterating, let’s see what breaks as today’s market and sector appears vulnerable” …


Pre-open indication results:  7 HITs < BioLife Solutions (BLFS +$3.51), Alnylam Pharmaceuticals (ALNY -$5.49), Ionis Pharmaceuticals (IONS -$12.05), CRISPR Therapeutics (CRSP -$6.51), Editas Medicine (EDIT -$2.40), Intellia Therapeutics (NTLA -$4.17), uniQure NV (QURE -$3.29) and 1 MISS < Biostage (BSTG +$0.04 with 1001 shares “the pump and promote is back”),


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Tuesday opened negative at 2/30, 2 flat and 1 acquired, stayed negative at the mid-day to 3/31 and 1 acquired, closing negative at 4/31 and 1 acquired;

There are clear winners and losers

Jumping with share pricing momentum:

  • BioLife Solutions (BLFS), Biostage (BSTG – promoted), MiMedx (MDXG) to name 3 of the 3 inclining of the 35 covered

Hammered in today’s market:

  • Ionis Pharmaceuticals (IONS), Ultragenyx (RARE), CRISPR Therapeutics (CRSP), Sage Therapeutics (SAGE), Alnylam Pharmaceuticals (ALNY) to name 5 of the 31 declining of the 35 covered


Key metrics:

  • Sector volume had LOW with 1 of the 3-upside having higher than the 3-month average volume with the volume of 12 of 31-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 3-upside were +1.70% (MDXG) to +8.48% (BLFS) while the 31-downside ranges from -1.93% (MESO) to -21.66% (IONS);


Tuesday’s (3 of 3) incline

  • BioLife Solutions (+$3.41 after Q4 earnings’ loss, merger and Monday’s -$0.19);
  • MiMedx (MDXG+$0.18 after Monday’s +$0.42);
  • Biostage (BSTG +$0.04 after Monday’s +$0.05 – “promoted and pimped”)

Tuesday’s (10 of 31) decliners:

  • Ionis Pharmaceuticals (IONS -$12.05 after a compound failure with Roche after Monday’s +$1.43);
  • Ultragenyx (RARE -$6.57 after Monday’s -$1.16);
  • CRISPR Therapeutics (CRSP -$6.51 after Monday’s +$3.39);
  • Sage Therapeutics (SAGE -$5.75 after Monday’s +$2.82);
  • Alnylam Pharmaceuticals (-$5.59 after Monday’s -$0.01)
  • Fate Therapeutics (FATE -$4.73 after Monday’s +$1.63);
  • uniQure NV (-$3.29 after Monday’s +$1.23);
  • Intellia Therapeutics (NTLA -$3.17 after Monday’s +$2.68);
  •  ReNeuron (RENE.L -$3.00 after Monday’s -$1.00);
  • Editas Medicine (EDIT -$2.40 after Monday’s +$3.48);

Closing: 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • U.S. trial data released Monday showed the Covid vaccine developed by AstraZeneca (AZN) and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.

Infection cases <Million>: never to forget …

  • Tuesday 29.82 M cases,
  • Tuesday’s death rate totaled 542,379 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -3.93% and XBI closed down -5.83%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +1.42 points or +7.52% at 20.30

Upside volume: low

  • Tuesday: 1 out of the 3-upside had higher than the 3-month average volume;

Downside volume: low

  • Tuesday: 12 out of the 31-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Tuesday’s percentage (%) of the 3-upside were +1.70% (MDXG) to +8.48% (BLFS) while the 31-downside ranges from -1.93% (MESO) to -21.66% (IONS);


March, the 3rd month of Q1/21:

Tuesday closed negative with 3 advancers, 31 decliners and 1 acquired

Monday (3/22) closed negative with 16 advancers, 18 decliners and 1 acquired


The BOTTOM LINE: Just another roller-coaster ride that cost us money but, it still shows sustainability is the real issue in “this” market!

For the record,” Tuesday also marks the anniversary of the pandemic lows on March 23, 2020, when all of the major U.S. stock benchmarks put in their bear-market lows, as the coronavirus pandemic plunged the U.S. into recession, before staging a powerful rebound, aided at least partly by a cocktail of fiscal spending and monetary-policy intervention.”

NOT for me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run as volatility rules!

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice has been … trim and skim … if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.